A three component mix of thioredoxin-L2 antigens elicits broadly neutralizing responses against oncogenic human papillomaviruses
Authors:
Abstract
No abstract availableKeywords
Funding Information
- Thompson Information Services
- NCI
This publication has 25 references indexed in Scilit:
- Global cancer transitions according to the Human Development Index (2008–2030): a population-based studyThe Lancet Oncology, 2012
- Global burden of cancers attributable to infections in 2008: a review and synthetic analysisThe Lancet Oncology, 2012
- Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccineHuman Vaccines & Immunotherapeutics, 2012
- Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialThe Lancet Oncology, 2012
- The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 YearsThe Journal of Infectious Diseases, 2009
- Protection of Rabbits against Challenge with Rabbit Papillomaviruses by Immunization with the N Terminus of Human Papillomavirus Type 16 Minor Capsid Antigen L2Journal of Virology, 2007
- Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2Virology, 2005
- Human Papillomavirus and Oral Cancer: The International Agency for Research on Cancer Multicenter StudyJNCI: Journal of the National Cancer Institute, 2003
- Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical CancerNew England Journal of Medicine, 2003
- Minor Capsid Protein of Human Genital Papillomaviruses Contains Subdominant, Cross-Neutralizing EpitopesVirology, 2000